What is ProSolus?
ProSolus Pharmaceuticals operates as a specialized developer and manufacturer of advanced drug delivery systems, focusing primarily on transdermal and topical patch technologies. The company serves a diverse range of therapeutic categories, including pain management, cardiovascular health, and neurologic care. By maintaining a state-of-the-art facility in Miami, Florida, ProSolus provides end-to-end solutions that encompass everything from initial formulation to final packaging. Their market position is defined by a collaborative approach, partnering with global suppliers to enhance the efficacy and delivery precision of pharmaceutical products, thereby addressing critical gaps in patient care and medication adherence.
How much funding has ProSolus raised?
ProSolus has raised a total of $637K across 2 funding rounds:
Debt
$350K
Debt
$287K
Debt (2020): $350K with participation from PPP
Debt (2021): $287K led by PPP
Key Investors in ProSolus
PPP
Public-Private Partnership
What's next for ProSolus?
With the recent influx of capital, ProSolus is well-positioned to accelerate its research and development initiatives, particularly in the refinement of complex drug delivery systems. The company's strategic roadmap likely involves expanding its manufacturing throughput to meet the growing demand for non-invasive therapeutic solutions. As the pharmaceutical industry shifts toward more personalized and patient-centric delivery methods, ProSolus is poised to leverage its existing infrastructure to capture additional market share. Future growth will likely be driven by continued investment in formulation technology and the strengthening of its supply chain partnerships, ensuring that the company remains a preferred provider for clients seeking sophisticated, high-quality pharmaceutical manufacturing services.
See full ProSolus company page
